Maze Therapeutics Names Misbah Tahir as New CFO.

Maze Therapeutics has appointed Misbah Tahir as chief financial officer, effective immediately. Tahir brings over 20 years of experience scaling biotech companies and will drive the company's growth strategy as it prepares for key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026.

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for patients with kidney and metabolic diseases, has appointed Misbah Tahir as its chief financial officer (CFO), effective immediately. The appointment comes as the company prepares for several key clinical milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025, and initial data from its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026.

Misbah Tahir brings over 20 years of experience in the biopharmaceutical industry, most recently serving as CFO at IGM Biosciences, where he led the company's 2019 initial public offering and raised over $1 billion in financing. His extensive background includes senior finance positions at Dermira, Inc., Onyx Pharmaceuticals, Inc., and Human Genome Sciences Inc., where he played key roles in capital formation, pharma collaboration, and product launches. Tahir began his career at Amgen, Inc. after working as a management consultant at the consulting firm of Oliver Wyman. He holds an M.B.A. from the University of Michigan Business School and a B.A. in International Relations from the University of Pennsylvania.

Tahir's appointment comes at a pivotal time for Maze Therapeutics, which maintains a strong financial position with a cash runway extending into the second half of 2027. The company's Compass platform guides its pursuit of genetically validated targets, integrating variant discovery and functionalization to discover and advance oral small molecule programs with first- or best-in-class potential. Maze's pipeline is led by MZE829, an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, an oral SLC6A19 inhibitor advancing through Phase 1 with the potential to treat both chronic kidney disease (CKD) and phenylketonuria (PKU).

Jason Coloma, Ph.D., the company's chief executive officer, stated, "We’re thrilled to welcome Misbah as Maze’s Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026. Misbah’s proven track record in scaling biotech companies, combined with deep financial and operational expertise, will be instrumental in driving our growth strategy as we maintain our focus on clinical execution."

Misbah Tahir added, "Maze’s strong balance sheet and expected cash runway into 2H 2027, combined with its differentiated precision genetics platform, advancing clinical pipeline, and disciplined development approach have given the company the opportunity to create significant value for both patients and shareholders. I look forward to partnering with Jason and the entire leadership team to drive the next phase for Maze as we work together to harness the power of human genetics to develop potentially novel, small molecule precision medicines for patients with kidney and metabolic diseases."

References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142502/0/en/Maze-Therapeutics-Appoints-Misbah-Tahir-as-Chief-Financial-Officer.html
[2] https://www.stocktitan.net/news/MAZE/maze-therapeutics-appoints-misbah-tahir-as-chief-financial-5ehglry611f6.html